Zealand Pharma Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Public

  • Employees
  • 578

Employees

  • Stock Symbol
  • ZEAL

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $31.22
  • (As of Thursday Closing)

Zealand Pharma General Information

Description

Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

Contact Information

Formerly Known As
Ppt A/S, Connexon, Peptide Probe Technologie
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Sydmarken 11
  • 2860 Soborg
  • Denmark
+45 88
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
CSE
Vertical(s)
Corporate Office
  • Sydmarken 11
  • 2860 Soborg
  • Denmark
+45 88

Zealand Pharma Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Zealand Pharma Stock Performance

As of 19-Nov-2026, Zealand Pharma’s stock price is $31.22. Its current market cap is $2.07B with 66.3M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$31.22 $32.60 $31.22 - $85.89 $2.07B 66.3M 404K $6.91

Zealand Pharma Financials Summary

As of 30-Sep-2026, Zealand Pharma has a trailing 12-month revenue of $715M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 616,395 2,692,632 5,937,273 3,016,784
Revenue 714,888 1,392,231 9,094 49,745
EBITDA 459,009 1,019,548 (173,078) (102,057)
Net Income 480,443 975,258 (156,490) (102,125)
Total Assets 2,948,744 2,508,106 1,326,190 293,973
Total Debt 73,423 63,811 54,657 17,702
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Zealand Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Zealand Pharma‘s full profile, request access.

Request a free trial

Zealand Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based m
Drug Discovery
Soborg, Denmark
578 As of 2026

Wayne, PA
 

Aventura, FL
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Zealand Pharma Competitors (82)

One of Zealand Pharma’s 82 competitors is Aclaris Therapeutics, a Formerly VC-backed company based in Wayne, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aclaris Therapeutics Formerly VC-backed Wayne, PA
NewAmsterdam Pharma Formerly VC-backed Aventura, FL
Protagonist Therapeutics Formerly VC-backed Newark, CA
Rein Therapeutics Formerly VC-backed Austin, TX
MBX Biosciences Formerly VC-backed Carmel, IN
You’re viewing 5 of 82 competitors. Get the full list »

Zealand Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Zealand Pharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Zealand Pharma‘s full profile, request access.

Request a free trial

Zealand Pharma Acquisitions (2)

Zealand Pharma’s most recent deal was a Merger/Acquisition with Valeritas Holdings for . The deal was made on 02-Apr-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Valeritas Holdings 02-Apr-2020 Merger/Acquisition Drug Delivery
Encycle Therapeutics 22-Oct-2019 Merger/Acquisition Drug Discovery
To view Zealand Pharma’s complete acquisitions history, request access »

Zealand Pharma ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

26.86 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Zealand Pharma’s complete esg history, request access »

Zealand Pharma Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Zp Holding Spv Soeborg, Denmark 2014
V-Go Insulin Delivery Device Glostrup, Denmark

Zealand Pharma FAQs

  • When was Zealand Pharma founded?

    Zealand Pharma was founded in 1998.

  • Where is Zealand Pharma headquartered?

    Zealand Pharma is headquartered in Soborg, Denmark.

  • What is the size of Zealand Pharma?

    Zealand Pharma has 578 total employees.

  • What industry is Zealand Pharma in?

    Zealand Pharma’s primary industry is Drug Discovery.

  • Is Zealand Pharma a private or public company?

    Zealand Pharma is a Public company.

  • What is Zealand Pharma’s stock symbol?

    The ticker symbol for Zealand Pharma is ZEAL.

  • What is the current stock price of Zealand Pharma?

    As of 19-Nov-2026 the stock price of Zealand Pharma is $31.22.

  • What is the current market cap of Zealand Pharma?

    The current market capitalization of Zealand Pharma is $2.07B.

  • What is Zealand Pharma’s current revenue?

    The trailing twelve month revenue for Zealand Pharma is $715M.

  • Who are Zealand Pharma’s competitors?

    Aclaris Therapeutics, NewAmsterdam Pharma, Protagonist Therapeutics, Rein Therapeutics, and MBX Biosciences are some of the 82 competitors of Zealand Pharma.

  • What is Zealand Pharma’s annual earnings per share (EPS)?

    Zealand Pharma’s EPS for 12 months was $6.91.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process